Atriz Health, a global company providing precision medicine treatment, diagnosis and prevention services and a pioneer in next-generation telemedicine and radiotherapy, becomes the first company to apply the novel drug Lutetium (Lu177-PSMA) to the treatment of a patient Is. with prostate cancer in Portugal.
Nidanas, as its name indicates, is the union between diagnosis and therapy. It originated in the field of nuclear medicine and is characterized by the application of radiopharmaceuticals (or radioactively labeled molecules) that allow to effectively and directly diagnose and treat cancer and its metastases, at the same time surrounding tissue. protects against damage.
Treatment with Lu177-PSMA represents a great innovation for patients with prostate cancer and consists in the use of a molecule that binds PSMA – a protein present in tumor cells of this gland conjugated with the lutetium isotope -177. happens, will destroy the malignant cells. It is a new drug recently approved by the European Medicines Agency, and is indicated for patients with metastasis and progression of oncological disease following hormonal and/or chemotherapy treatments. The clinical trials that served as the basis for the approval of this drug by regulatory agencies showed that this treatment leads to a significant improvement in overall survival compared to conventional therapies.
The first use of this treatment in Portugal took place last Thursday in a patient with prostate cancer at one of three molecular medicine units in the Portuguese country of Atres.
“The presence of this new drug opens a new and promising line of application for the treatment of patients with prostate cancer, both in Portugal and in the rest of the countries where we are present,” says Antoine Giro, Managing Director of the Diagnostics Area. of Atries, as its use will be extended to all Atries Cancer Centers around the world.
In the specific case of Spain, the use of lutetium for certain types of cancer has already started in some of the company’s health centers, for example, for pediatric neuroendocrine cancer through SIMM Atris Nuclear Medicine at the Hospital Sant Joan de Deu. for treatment. Barcelona is one of the most important medical centers in the field of pediatric oncology worldwide.